北京浩天（广州）律师事务所 法律意见书 北京浩天（广州）律师事务所 关于贵州永吉印务股份有限公司 二〇二三年年度股东大会 法律意见书 2023 年年度股东大会之 法律意见书 （2024）粤浩律法字第 429 号 二〇二四年四月 北京浩天（广州）律师事务所 关于贵州永吉有印务股份有限公司 致：贵州永吉印务股份有限公司 根据中国证监会发布的《上市公司股东大会规则》（下称"《股东大会规则》"） 的有关规定，北京浩天（广州）律师事务所（下称"本所"）受贵州永吉印务股份 有限公司（下称"公司"）委托，指派律师出席公司 2023 年年度股东大会（下称"本 次股东大会"），并就本次股东大会的召集和召开程序、召集人资格、出席和列席 会议人员资格、表决程序及表决结果等事宜发表法律意见。 本所同意公司将本法律意见书随本次股东大会决议一并公告，且仅用于为本次 股东大会见证之目的，不得用作任何其他目的。 本所律师现场对本次股东大会进行见证，并根据《中华人民共和国公司法》（下 称"《公司法》"）、《股东大会规则》等法律、法规及规范性文件的要求，按照 律师行业公认的业务标准、道德规范和勤勉尽责精神，对本次股东大会的召集、召 开的有关事实 ...

股票代码：603058 2023 年年度股东大会 会议资料 贵州永吉印务股份有限公司 二零二四年四月二十三日 1 贵州永吉印务股份有限公司 股东大会会议须知 为了维护全体股东的合法权益、依法行使股东职权，确保股东大会的正常秩 序和议事效率，根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上 市公司股东大会规则》、《公司章程》及公司《股东大会议事规则》，制订本须知。 一、股东大会由董事会办公室具体负责有关程序方面的事宜。 二、会议期间全体出席会议人员应以维护股东合法权益、确保大会正常秩 序、提高议事效率为原则，认真履行法定职责。 三、为保证股东大会的严肃性和正常秩序，除依法出席会议的公司股东（或 其授权代表）、董事、监事、董事会秘书、高级管理人员、见证律师和董事会邀 请参会的人员外，公司有权依法拒绝其他人士入场。 | 目录 | | --- | | 股东大会会议须知 | 3 | | --- | --- | | 2023 年年度股东大会议程 | 4 | | 议案一：《公司 | 2023 年度董事会工作报告》 6 | | 议案二：《2023 | 年度监事会工作报告》 15 | | 议案三：《公司 | 202 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 224,351,811.57, representing a year-on-year increase of 29.04%[4] - The net profit attributable to shareholders for the same period was CNY 40,493,153.35, reflecting a growth of 31.02% compared to the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 41,409,014.63, which is an increase of 33.65% year-on-year[4] - The basic earnings per share for Q1 2024 was CNY 0.097, up by 34.72% from the same period last year[4] - The diluted earnings per share was CNY 0.096, showing a growth of 33.33% year-on-year[4] - Net profit for Q1 2024 reached CNY 43,358,592.94, representing a 43.5% increase from CNY 30,202,186.00 in Q1 2023[19] - The total comprehensive income for Q1 2024 was CNY 34,539,654.73, compared to CNY 26,494,899.22 in Q1 2023, indicating a growth of 30.5%[20] Cash Flow and Investments - The net cash flow from operating activities was negative at CNY -22,290,910.07, a decrease of 409.87% compared to the previous year[4] - The net cash flow from operating activities for Q1 2024 was negative CNY 22,290,910.07, a decline from a positive CNY 7,193,699.34 in Q1 2023[23] - In Q1 2024, the net cash flow from investing activities was -$39.27 million, compared to $114.79 million in the previous period[24] - The total cash inflow from financing activities was $20 million, while the cash outflow was $16.8 million, resulting in a net cash flow of $3.2 million[24] - The net increase in cash and cash equivalents for the period was -$58.75 million, down from an increase of $119.71 million in the previous year[24] - The ending balance of cash and cash equivalents was $101.46 million, significantly lower than $376.18 million at the end of the previous period[24] - The company received $20 million in cash from borrowings during the financing activities[24] - Cash paid for debt repayment was $15.1 million, slightly higher than $14.8 million in the previous period[24] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,923,381,742.45, a slight increase of 0.78% from the end of the previous year[5] - Total current assets as of March 31, 2024, amounted to CNY 793,040,102.16, up from CNY 765,179,311.66 at the end of 2023, reflecting a growth of 3.7%[14] - Accounts receivable increased to CNY 341,939,666.18 from CNY 281,968,554.96, representing a rise of 21.3%[14] - Non-current assets totaled CNY 1,130,341,640.29, a decrease of 1.1% from CNY 1,143,330,013.85 at the end of 2023[15] - Total liabilities decreased to CNY 685,486,073.90 from CNY 707,104,021.83, a reduction of 3.1%[16] - The company's cash and cash equivalents decreased to CNY 120,658,463.94 from CNY 178,893,448.06, a decline of 32.5%[14] - Short-term borrowings increased to CNY 40,000,000.00 from CNY 20,000,000.00, marking a 100% increase[15] - The company's retained earnings rose to CNY 437,008,725.14 from CNY 396,515,571.79, an increase of 10.2%[16] Operating Costs and Expenses - Total operating costs for Q1 2024 were CNY 167,438,104.72, an increase of 20.2% compared to CNY 139,355,496.58 in Q1 2023[19] - Research and development expenses for Q1 2024 were CNY 9,081,124.25, slightly down from CNY 9,202,666.51 in Q1 2023[19] - The tax expenses for Q1 2024 were CNY 7,484,293.97, an increase from CNY 5,679,584.44 in Q1 2023[19] - The company incurred a net investment loss of CNY 616,168.42 in Q1 2024, a significant improvement from a loss of CNY 504,436.89 in Q1 2023[19] - Non-recurring losses totaled CNY -915,861.28, primarily due to losses from financial assets and other operating expenses[6] Revenue Sources - The company attributed the revenue growth primarily to significant increases in overseas medical cannabis sales and new customers for cigarette labels outside the province[7] - Revenue from sales of goods and services in Q1 2024 was CNY 181,235,983.10, down 18.8% from CNY 223,218,263.76 in Q1 2023[23] Other Information - Cash dividends proposed for 2023 are CNY 0.8 per 10 shares, subject to approval at the annual shareholders' meeting[11] - The company did not apply new accounting standards or interpretations for the first time in 2024[24] - The weighted average return on net assets was 3.72%, an increase of 0.82% compared to the previous year[5] - Other comprehensive income after tax for Q1 2024 was negative CNY 8,818,938.21, worsening from negative CNY 3,707,286.78 in Q1 2023[20]

贵州永吉印务股份有限公司 关于"永吉转债"付息的公告 | 证券代码：603058 | 证券简称：永吉股份 公告编号：2024-024 | | --- | --- | | 转债代码：113646 | 转债简称：永吉转债 | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 贵州永吉印务股份有限公司（以下简称"公司"）于 2022 年 4 月 14 日发行 的可转换公司债券将于 2024 年 4 月 15 日开始支付自 2023 年 4 月 14 日至 2024 年 4 月 13 日期间的利息。根据本公司《公开发行可转换公司债券募集说明书》 有关条款的规定，现将有关事项公告如下： 一、可转债发行上市概况 根据《上海证券交易所股票上市规则》等有关规定和《贵州永吉印务股份有 限公司公开发行可转换公司债券募集说明书》（以下简称"《募集说明书》"） 的相关条款规定，永吉转债自 2022 年 10 月 20 日起可转换为本公司股份。 可转债付息债权登记日：2024 年 4 月 12 日 可转债除息日：2024 年 4 月 15 ...

贵州永吉印务股份有限公司 可转债转股结果暨股份变动公告 | 证券代码：603058 | 证券简称：永吉股份 | 公告编号：2024-022 | | --- | --- | --- | | 转债代码：113646 | 转债简称：永吉转债 | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 转股情况："永吉转债"自2022年10月20日开始转股，截至2024年3月31 日，累计共有人民币7,708,000.00元"永吉转债"已转换成公司股票，累计转股 数量为906,132股，占可转债转股前公司已发行股份总额的0.2162%。 ● 未转股可转债情况：截至2024年3月31日，尚未转股的"永吉转债"金额 为人民币138,160,000.00元，占可转债发行总量的94.7158%。 ● 本季度转股情况：自2024年1月1日至2024年3月31日，共有9,000.00元 "永吉转债"转换成公司股票，本期因转股形成的股份数量为1,089股。 一、可转债发行上市概况 经中国证券监督管理委员会证监许可[2021]2509 ...

| 证券代码：603058 | 证券简称：永吉股份 公告编号：2024-020 | | --- | --- | | 转债代码：113646 | 转债简称：永吉转债 | 贵州永吉印务股份有限公司 关于控股股东部分股票质押展期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 贵州永吉印务股份有限公司（以下简称"公司"）控股股东贵州永吉控 股有限责任公司（以下简称"永吉控股"）持有公司股份 151,566,200 股，占公 司总股本的 36.09%，本次质押展期后,永吉控股累计质押股份 84,557,400 股， 占其持股总数的 55.79%，占本公司总股本的 20.13%。 ● 截至本公告披露日，公司控股股东贵州永吉控股有限责任公司与实际控制 人邓维加及邓代兴合计持有公司股份 197,047,700 股，占公司总股本的 46.92%； 公司控股股东及实际控制人累计质押本公司股份 114,036,300 股，占其合计所持 公司股份数量的 57.87%，占本公司总股本的 27.15%。 公司于 2024 年 ...

关于《贵州永吉印务股份有限公司关于控股股东及实 邓维力 邓代兴 际控制人是否存在重大事项的问询函》的函复 贵州永吉印务股份有限公司: 来函收悉。经我司核实并向实际控制人邓维加、邓代兴先生问询，截至2024 年3月29日,除贵司已公开披露的信息外,我司及实际控制人邓维加、邓代兴先 生不存在影响贵司股票交易价格异常波动的重大事项,亦不存在其他应披露而未 披露的重大信息, 包括但不限于重大资产重组、股份发行、收购、债务重组、 业务重组、资产剥离、资产注入、股份回购、股权激励、破产重整、重大业务 合作、引进战略投资者等重大事项。 特此函复。 ...

| 证券代码：603058 | 证券简称：永吉股份 | 公告编号：2024-021 | | --- | --- | --- | | 转债代码：113646 | 转债简称：永吉转债 | | 贵州永吉印务股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 贵州永吉印务股份有限公司（以下简称"公司"）股票于 2024 年 3 月 27 日、2024 年 3 月 28 日、2024 年 3 月 29 日连续三个交易日内日收盘价格涨幅偏 离值累计超过 20%，根据《上海证券交易所交易规则》的有关规定，属于股票交 易异常波动情形。 ● 经公司自查，并发函询问控股股东和实际控制人，截至本公告披露日， 不存在应披露而未披露的重大信息。 ● 重大风险提示： （一）二级市场交易风险 公司股票于 2024 年 3 月 27 日、2024 年 3 月 28 日、2024 年 3 月 29 日连续 三个交易日内日收盘价格涨幅偏离值累计超过 20%，敬请广大投资者注意二级市 场交易风险，理性 ...

Financial Performance - The net profit attributable to the parent company's shareholders for 2023 is RMB 100,152,353.14, with undistributed profits amounting to RMB 274,772,539.21 as of December 31, 2023[6]. - The company's operating revenue for 2023 reached CNY 817,697,733.09, representing a year-on-year increase of 25.16%[25]. - The net profit attributable to shareholders for 2023 was CNY 100,152,353.14, a significant increase of 165.11% compared to the previous year[27]. - The net profit after deducting non-recurring gains and losses was CNY 94,575,058.99, up 14.32% year-on-year, driven by improved production efficiency and cost reduction efforts[27]. - The basic earnings per share for 2023 was CNY 0.2412, reflecting a growth of 164.76% from the previous year[26]. - The weighted average return on equity increased by 6.11 percentage points to 9.52% in 2023, attributed to the company's profit growth[26]. - The net cash flow from operating activities for 2023 was CNY 31,103,809.30, a decrease of 68.97% due to increased tax payments[27]. - Total assets at the end of 2023 amounted to CNY 1,908,509,325.51, an increase of 8.43% from the previous year[26]. Dividend Distribution - The proposed cash dividend distribution is RMB 0.8 per 10 shares, totaling RMB 33,584,291.44 (including tax) based on a total share capital of 419,979,443 shares[6]. - The cash dividend for 2022 represents 33.53% of the net profit attributable to ordinary shareholders in the consolidated financial statements[164]. - The company plans to distribute a cash dividend of 2.5 RMB per 10 shares, totaling approximately 104,772,764 RMB for the 2022 fiscal year[159]. Corporate Governance - The company has a comprehensive governance structure with all board members present at the board meeting[4]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal requirements[125]. - The company has implemented measures to ensure the independence of its operations from its controlling shareholders[126]. - The company has committed to improving its corporate governance structure and ensuring accurate and timely information disclosure[124]. Market Expansion and Product Development - The company maintains a focus on expanding its market presence and developing new products and technologies[12]. - The company plans to maintain its growth trajectory by expanding its product offerings and optimizing operational efficiency[27]. - The company is actively expanding into the medical cannabis sector, focusing on the research and production of cannabis-related applications, aiming to cultivate new profit growth points[51]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 100 million CNY allocated for potential deals[135]. - The company plans to increase its cannabis production capacity with the new 10,000 square meter greenhouse expected to add 2,000 kg of capacity in 2023[71]. Research and Development - The company invested 46.62 million yuan in R&D, reflecting a 32.26% increase, and developed a total of 258 new products, with 68 already in production[37]. - The company is investing 30 million CNY in R&D for new technologies aimed at enhancing production efficiency[135]. - Research and development expenses totaled CNY 46,618,487.99, accounting for 5.70% of total revenue[89]. Environmental Responsibility - The company has received a pollution discharge permit from the Guiyang Ecology and Environment Bureau[180]. - The company has a zero discharge policy for production wastewater, with monitoring conducted once a year at the sewage discharge point[186]. - The company has committed to measures to mitigate the dilution of immediate returns due to the issuance of convertible bonds, ensuring compliance with regulatory requirements[195]. - The company has established an emergency response plan for environmental pollution incidents, which has been filed with local environmental authorities[181]. Risk Management - The company emphasizes that forward-looking statements do not constitute substantive commitments to investors, highlighting potential investment risks[7]. - The company is closely monitoring exchange rate fluctuations, particularly between the RMB and AUD, to manage foreign exchange risks[122]. - The company has implemented risk management thresholds for its secondary market investments to ensure investment safety[121]. Employee and Management Structure - The company reported a total of 1,066 employees, with 534 in the parent company and 532 in major subsidiaries[153]. - The employee composition includes 700 production personnel, 25 sales personnel, 172 technical personnel, 17 financial personnel, and 152 administrative personnel[153]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 6.945434 million yuan[139]. Financial Health and Investments - The company’s cash and cash equivalents decreased by 36.81% from the previous period, totaling 178,893,448.06 CNY, which accounted for 9.37% of total assets[96]. - The company has initiated a one-year working capital loan of 20,000,000 CNY, marking a new addition to its short-term borrowings[96]. - The company plans to invest up to 50 million yuan in private equity funds to enhance returns and improve capital efficiency[120]. Strategic Partnerships and Collaborations - The company has established strategic partnerships with key research institutions and suppliers, engaging in over 30 joint development projects for new products and technologies[62]. - The company has established a strong cooperative relationship with Guizhou Zhongyan, which remains its largest customer, contributing significantly to sales[118].

| 证券代码：603058 | 证券简称：永吉股份 公告编号：2024-009 | | --- | --- | | 转债代码：113646 | 转债简称：永吉转债 | 贵州永吉印务股份有限公司 关于2023年日常关联交易确认及2024 年拟发生关联交易情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本日常关联交易预计事项需提交股东大会审议。 ● 日常关联交易对上市公司的影响：本次关联交易属公司日常关联交易， 是正常生产经营业务，以市场价格为定价依据，遵循平等自愿原则，交易风险可 控，不存在损害公司及股东利益的情况，不会对关联人形成较大的依赖。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 贵州永吉印务股份有限公司（以下简称"公司"）于2024年3月28日召开第 五届董事会第二十七次会议，审议通过了《关于公司2023年日常关联交易情况以 及2024年度拟发生关联交易的议案》，公司关联董事回避表决，出席会议的非关 联董事一致同意通过该议案。本议案在提交董事会审议前已经董事会独立董事专 ...